We believe
Collaboration is The Key
It is what forwards healthcare and advances scientific endeavours.
Why Collaborate With Us?
State-of-the-Art Infrastructure
powering advanced research and innovation.
Collaborative Knowledge
enabling seamless information exchange and discovery.
Expert Research Access
connecting to specialised scientific expertise.
Breakthrough Innovations
accelerating drug development and addressing unmet medical needs.
Over Two Decades of Expertise
in Biologics.
Areas of Interest
External Collaborations
Partnering with global innovators to enhance Biologics R&D, from optimised mAb expression systems to advanced drug delivery and toxicity testing.
Academic Collaborations
Engaging with top institutes through PhD programmes and research partnerships to drive scientific advancements in Biologics.
How We Collaborate
Some scopes that the various teams at Dr. Reddy’s Biologics have explored are presented here. We truly believe that scientific collaborations are key to solving problems and, hence, are open to scientific collaboration opportunities in the space of Biosimilars.
External Collaborations
Scope
External Collaborators
Cytiva
(Hyclone, USA)
Merck
(Millipore/SAFC, USA)
ThermoFisher
(USA)
Academic Collaborations
MoUs with leading institutes for PhD programmes
BITS Pilani Hyderabad
Mahindra University
(Hyderabad, India)
Internal Business Units Collaborations
IPDO
Business Unit
Scope
Proof-of-concept (POC) studies for antibody-drug conjugate product
Aurigene Pharmaceutical Services Ltd (APSL)
Business Unit/Subsidiaries of Dr.Reddys
Scope
Process development for new bispecific molecules
Aurigene Oncology Limited (AOL)
Business Unit/Subsidiaries of Dr.Reddys
Scope
Driving discovery of New Biological Entities (NBEs)
DRILS
Business Unit/Subsidiaries of Dr.Reddys
Scope
Scientific collaborations for mRNA POC activities
- Publication
- 31-03-2025
Abstract No: 0556, ISNCON Conference 2014 A Randomized, Comparative, Open-label Clinical Trial of Darbepoetin Alfa Biosimilar for the Treatment of Anaemia in Pre-Dialysis Chronic Kidney Disease Patients
- Publication
- 23-04-2025
Abstract No: 0556, ISNCON Conference 2014 Efficacy and Safety of Indigenously Developed Darbepoetin Alfa in Dialysis Patients - A Randomised Study
- News
- 07-06-2025
Alvotech and Dr. Reddy’s to co-develop biosimilar candidate to Keytruda® (pembrolizumab)
- Publication
- 12-02-2020
Pharmacokinetic Similarity and Comparative Pharmacodynamics, Safety, Efficacy, and Immunogenicity of DRL_RI Versus ReferenceRituximab in Biologics‑Naïve Patients with Moderate‑to‑SevereRheumatoid Arthritis: A Double‑Blind, Randomized, Three‑Arm Study
Anirudha Ajay S
Manufacturing
Uday Kiran
Quality
Mushfira S
Product Dev.
Punitha P
Quality
Krishna Mohan B
Quality
Bricks of Biologics, appreciates the contribution and celebrates our people who are the building blocks of Dr. Reddy's Biologics.
Bricks of biologics in general refers to bio-bricks as genetic building blocks which are DNA sequences that can be assembled to create complex biological systems.